

## CV of Dr. Maria R. CAPOBIANCHI

**Birth date:** July 30, 1953    **Place:** Procida (Naples, Italy)



### Education

1972: High school diploma, Naples  
1976: Biological Sciences Degree, University of Naples  
1988: Ph.D. in Microbiology, University of Rome

### Past positions:

1977-1981: Fellow of the National Research Council, Institute of Virology, Rome  
1981-1999: Assistant Professor, University of Rome, "La Sapienza" Medical School.  
1989-1999: Assistant Director, Virology Diagnostic Service, University Polyclinic "Umberto I", Rome

**Present position:** Director of the Laboratory of Virology (since 2000); Director of the Department of Epidemiology, Preclinical Research and Advanced Diagnostics (since 2015), National Institute of Infectious Diseases "L. Spallanzani", Rome, Italy.

### Address:

Laboratory of Virology  
National Institute of Infectious Diseases "L. Spallanzani"  
Via Portuense 292  
00149 Rome, Italy  
Tel +390655170434; fax +39065582346  
e-mail: maria.capobianchi@inmi.it

### Editorial activity

**2011-today:** Member of the Editorial board of Vector-Borne and Zoonotic Diseases  
**2010-today:** Member of the Editorial Board of New Microbiologica  
**2008-today:** Member of the Editorial Board of The Open Hepatology Journal  
**1997, 2001, 2008:** Coauthor of the book: Manuale di Virologia Medica. Mc Graw Hill, Milan, three editions  
**1999-2008:** Member of the Editorial Board of J. Biological Regulators & Homeostatic Agents

### Official designations

**2002-today:** Italian Representative in the Global Health Security Action Group (GHSAG)-laboratory network

**2009-2012:** Member of the National Transplant Council commission for audit of laboratory activities in the organ donor screening

**2011-2014:** Advisory board member of the project Episouth Plus established by the European Commission

**2013-today:** Member of the expert panel for the compilation of Italian Guidelines for management of HIV infection in adults, reviewed annually

**2015:** Scientific advisory board member of the project Virogenesis established by the European Commission

**2014-today:** Responsible of the national reference Laboratory for Ebola and other risk group 4 infections

**2012-today:** Appointed as expert for the EU-funded project "Establishment of Mobile Laboratories for Pathogens up to Risk Group 4 in combination with CBRN Capacity Building in sub-Saharan Africa"

**2017-today:** Member of the board of experts for the implementation of the national plan of polio eradication

**2019:** Contract professor, Molecular Biology (Bio 11), Saint Camillus International University of Health Sciences (Unicamillus), Rome

**Scientific interests:**

- Innate immunity and defence mechanisms against viruses
- Interferon induction and action
- Persistent viral infections (Viral Hepatitis, HIV and Herpesvirus infections)
- Pathogenesis of AIDS
- Emerging viruses
- Viral infections in the immunocompromised hosts
- Mechanisms of resistance to antivirals
- Development, standardization and validation of advanced virological tests
- Development of laboratory response to emerging viral diseases and to bioterrorism
- Biosafety

**Health care activity:**

- Virology diagnostic service
- Virological expertise for clinical research projects
- Director of the BSL-3/BSL-4 laboratory facility at the National Institute of Infectious Diseases "L. Spallanzani", Rome, Italy.
- Coordinator of the laboratory response to emerging infectious diseases, including those originated from deliberate release
- Chairperson of the Institutional Biosafety Committee
- Regional reference center for:
  - Viral infections in transplanted patients
  - Emerging viral infections
  - Virological surveillance of rubella and measles
  - Virological surveillance of severe influenza and other viral respiratory infections
  - Virological surveillance of viral hepatitis transmitted through the oro-fecal route (HAV and HEV)
  - Virological surveillance of arthropod borne viral infections
- National reference center for the diagnosis of:
  - High threat viral infections including those caused by RG4 viruses
  - Infections caused by deliberate release

**Scientific Society Membership**

- Italian Society of Microbiology (SIM)
- Italian Association for Clinical Microbiology (AMCLI)
- Italian Society of Virology (SIV-ISV)
- International Society for Interferon & Cytokine Research (ISICR)
- European Society for Clinical Microbiology and Infectious Diseases (ESCMID)
- European Society of Virology (ESV)

**Networking activity and participation to international research projects**

- Global Virology Network (GVN)
- Global Health Security Action Group (GHSAG)-laboratory network
- WHO-Emerging and Dangerous Pathogens Laboratory Network (EDPLN)
- WHO GOARN (Global Outbreak Alert and Response Network)
- ECDC EVD-LabNet (Emerging Viral Diseases-Expert Laboratory Network)

- Food and Drug Administration funded project: Field Validation of BSL-2 assay to diagnose total and neutralizing anti-Ebola antibodies in West Africa

#### **EU-supported networks/projects:**

- ENP4Lab (European Network of P4 Laboratories)
- ERINHA (European Research Infrastructure on Highly Pathogenic Agents)
- PREDEMICS (Prediction and Prevention of Emerging Zoonotic Viruses with Pandemic Potential using Multidisciplinary Approaches)
- QUANDHIP (Quality Assurance Exercises and Networking on the Detection of Highly Infectious Pathogens)
- EPISOUTH PLUS (A network for the control of public health threats and other bio-security tasks in the Mediterranean region and Balkans)
- EMobile Lab, "Establishment of Mobile Laboratories for Pathogens up to Risk Group 4 in combination with CBRN Capacity Building in sub-Saharan Africa".
- EDPLN (WHO Emerging and Dangerous Pathogens Laboratory Network)
- EVAg (European Virus Archive goes Global)
- FiloDiag (Ultra-Fast Molecular Filovirus Diagnostics)
- EbolaMODRAD (Ebola Virus: Modern Approaches for developing bedside Rapid Diagnostics)
- EVIDENT (Ebola Virus Disease - correlates of protection, determinants of outcome, and clinical management)
- IF-Ebola (Control of the Ebola Outbreak by both innovative Ultrasensitive Detection of EBOV and therapy)
- MOFINA (Mobile Filovirus Nucleic Acid Test)

#### **Publications**

Dr Capobianchi is author/co-author of than 474 publications, including 398 peer reviewed articles (source: PubMed, <https://www.ncbi.nlm.nih.gov/pubmed/?term=Capobianchi+M>, accessed: Dec. 16, 2019), with 7.657 citations. H index: 43, excluding self citations; (Source: Scopus, <https://www.scopus.com/hirsch/author.uri?accessor=authorProfile&auidList=7006361490&authorName=Capobianchi%2c+Maria+Rosaria&origin=AuthorProfile&display=hIndex&documentCount=412%2c412&txGid=296add41bedfbc93aff53813a31c4d51>); she is among the list of Via-Academy's Top Italian Scientists ([http://www.topitalianscientists.org/Top\\_italian\\_scientists\\_VIA-Academy.aspx](http://www.topitalianscientists.org/Top_italian_scientists_VIA-Academy.aspx)).

#### **Recent publications list (2018 onward)**

1. Biava M, Caglioti C, Castilletti C, Bordi L, Carletti F, Colavita F, Quartu S, Nicastrì E, Iannetta M, Vairo F, Liuzzi G, Taglietti F, Ippolito G, Capobianchi MR. Persistence of ZIKV-RNA in the cellular fraction of semen is accompanied by a surrogate-marker of viral replication. Diagnostic implications for sexual transmission. *New Microbiologica*. 41, 30-33, 2018.
2. Dirani G, Paesini E, Mascetra E, Farabegoli P, Dalmo B, Bartolini B, Garbuglia AR, Capobianchi MR, Sambri V. A novel next generation sequencing assay as an alternative to currently available methods for hepatitis C virus genotyping. *J Virol Methods*. 251:88-91, 2018.
3. Bordi L, Carletti F, Lalle E, Colavita F, Meschi S, Di Caro A, Nicastrì E, Scognamiglio P, Vairo F, Di Lallo D, Panella V, Capobianchi MR, Ippolito G, Castilletti C. Molecular Characterization of Autochthonous Chikungunya Cluster in Latium Region, Italy. *Emerg Infect Dis*. 15;24, 2018.
4. Cimini E, Bordoni V, Sacchi A, Visco-Comandini U, Montalbano M, Taibi C, Casetti R, Lalle E, D'Offizi G, Capobianchi MR, Agrati C. Intrahepatic V $\gamma$ 9V $\delta$ 2 T-cells from HCV-infected patients show an exhausted phenotype but can inhibit HCV replication. *Virus Res*. 243:31-35, 2018.
5. Lanini S, Portella G, Vairo F, Kobinger GP, Pesenti A, Langer M, Kabia S, Brogiato G, Amone J, Castilletti C, Miccio R, Capobianchi MR, Strada G, Zumla A, Di Caro A, Ippolito G; INMI-EMERGENCY EBOV Sierra Leone Study Group . Relationship Between Viremia and Specific Organ Damage in Ebola Patients: A Cohort Study. *Clin Infect Dis*. 66:36-44, 2018.
6. Vergori A, Garbuglia AR, Piselli P, Del Nonno F, Sias C, Lupi F, Lapa D, Baiocchini A, Cimaglia C, Gentile M, Antinori A, Capobianchi M, Ammassari A. Oral human Papillomavirus DNA detection in HIV-positive men: prevalence, predictors, and co-occurrence at anal site. *BMC Infect Dis*. 18:25, 2018.
7. Biava M, Colavita F, Marzorati A, Russo D, Pirola D, Cocci A, Petrocelli A, Delli Guanti M, Cataldi G, Kamara TA, Kamara AS, Konneh K, Cannas A, Coen S, Quartu S, Meschi S, Valli MB, Mazzarelli A, Venditti C, Grassi G, Rozera G, Castilletti C, Mirazimi A, Capobianchi MR, Ippolito G, Miccio R, Di Caro A.. Evaluation of a rapid and sensitive RT-qPCR assay for the detection of Ebola Virus. *J Virol Methods*. 252:70-

74, 2018.

8. Spada E, Rezza G, Garbuglia AR, Lombardo FL, Zuccaro O, Menniti Ippolito F, Cupellaro E, Capone S, Capobianchi MR, Nicosia A, Cortese R, Folgori A, Mele A; Collaborative Study Group. Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy. *J Urban Health*. 95:99-110, 2018.
9. Colson P, Capobianchi MR. International Journal of Antimicrobial Agents Themed Section Issue: "Therapeutics of hepatitis viruses". *Int J Antimicrob Agents*. 2018 Mar 21. pii: S0924-8579(18)30082-7.
10. Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, De Wit S, Dabis F, Pradier C, d'Arminio Monforte A, Kovari H, Law M, Lundgren JD, Sabin CA; Data Collection of Adverse Events of Anti-HIV drugs (D:A:D) Study group. Gender differences in the use of cardiovascular interventions in HIV-positive persons; the D:A:D Study. *J Int AIDS Soc*. 21, 2018.
11. Lalle E, Colavita F, Iannetta M, Gebremeskel Teklè S, Carletti F, Scorzolini L, Bordi L, Vincenti D, Castilletti C, Ippolito G, Capobianchi MR, Nicastrì E. Prolonged detection of dengue virus RNA in the semen of a man returning from Thailand to Italy, January 2018. *Euro Surveill*. 23, 2018.
12. Colavita F, Biava M, Mertens P, Gillemann Q, Borlon C, Delli Guanti M, Petrocelli A, Cataldi G, Kamara AT, Kamara SA, Konneh K, Vincenti D, Castilletti C, Abdurahman S, Mirazimi A, Capobianchi MR, Ippolito G, Miccio R, Di Caro A. EBOLA Ag K-SeT rapid test: field evaluation in Sierra Leone. *Clin Microbiol Infect*. 24:653-657, 2018.
13. Colavita F, Bordoni V, Caglioti C, Biava M, Castilletti C, Bordi L, Quartu S, Iannetta M, Ippolito G, Agrati C, Capobianchi MR, Lalle E. ZIKV Infection Induces an Inflammatory Response but Fails to Activate Types I, II, and III IFN Response in Human PBMC. *Mediators Inflamm*. 2018:2450540, 2018.
14. Menzo S, Minosse C, Vincenti D, Vincenzi L, Iacomi F, Zaccaro P, D'Offizi G, Capobianchi MR. Long-Term Follow-Up of Acute Hepatitis B: New Insights in Its Natural History and Implications for Antiviral Treatment. *Genes (Basel)*. 9(6), 2018.
15. Visco-Comandini U, Lapa D, Lionetti R, Taibi C, Loiacono L, Montalbano M, Capobianchi MR, D'Offizi G, Garbuglia AR. Significance of detectable HCV RNA below the limit of quantification in patients treated with DAAs using standard and ultrasensitive protocols. *J Med Virol*. 90(7):1264-1271, 2018.
16. Puro V, Fusco FM, Castilletti C, Carletti F, Colavita F, Agrati C, Di Caro A, Capobianchi MR, Ippolito G. Occupational transmission of an Orthopoxvirus infection during an outbreak in a colony of *Macaca tonkeana* in Lazio Region, Italy, 2015. *Zoonoses Public Health*. 65: 578-583, 2018.
17. Mussini C, Lorenzini P, Cozzi-Lepri A, Marchetti G, Rusconi S, Gori A, Nozza S, Lichtner M, Antinori A, Cossarizza A, d'Arminio Monforte A; Icona Foundation Study Group. Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. *BMC Med*. 16:79, 2018.
18. Taramasso L, Di Biagio A, Maggiolo F, Tavelli A, Lo Caputo S, Bonora S, Zaccarelli M, Caramello P, Costantini A, Viscoli C, d'Arminio Monforte A, Cozzi-Lepri A; Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group. First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. *HIV Med*. 2018 May 30. doi: 10.1111/hiv.12628.
19. Romette JL, Prat CM, Gould EA, de Lamballerie X, Charrel R, Coutard B, Fooks AR, Bardsley M, Carroll M, Drosten C, Drexler JF, Günther S, Klempa B, Pinschewer D, Klimkait T, Avsic-Zupanc T, Capobianchi MR, Di Caro A, Ippolito G, Nitsche A, Koopmans M, Reusken C, Gorbalenya A, Raoul H, Bourhy H, Mettenleiter T, Reiche S, Batten C, Sabeta C, Paweska JT, Eropkin M, Zverev V, Hu Z, Mac Cullough S, Mirazimi A, Pradel F, Lieutaud P. The European Virus Archive goes global: A growing resource for research. *Antiviral Res*. 158:127-134, 2018.
20. Lanini S, Pisapia R, Capobianchi MR, Ippolito G. Global epidemiology of viral hepatitis and national needs for complete control. *Expert Rev Anti Infect Ther*. 16:625-639, 2018.
21. Saracino A, Zaccarelli M, Lorenzini P, Bandera A, Marchetti G, Castelli F, Gori A, Girardi E, Mussini C, Bonfanti P, Ammassari A, d'Arminio Monforte A; Icona Foundation Study Group. Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. *BMC Public Health*. 18:870, 2018.
22. Vairo F, Di Pietrantonj C, Pasqualini C, Mammone A, Lanini S, Nicastrì E, Castilletti C, Ferraro F, Di Bari V, Puro V, Scognamiglio P, Di Caro A, Capobianchi MR, Ippolito G. The Surveillance of Chikungunya Virus in a Temperate Climate: Challenges and Possible Solutions from the Experience of Lazio Region, Italy. *Viruses*. 10(9), 2018.
23. Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, Marchetti G, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group. Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. *J Antimicrob Chemother*. 73:3460-3470, 2018.
24. Santangelo L, Bordoni V, Montaldo C, Cimini E, Zingoni A, Battistelli C, D'Offizi G, Capobianchi MR, Santoni A, Tripodi M, Agrati C. Hepatitis C virus direct-acting antivirals therapy impacts on extracellular vesicles microRNAs content and on their immunomodulating properties. *Liver Int*. 38:1741-1750, 2018.
25. Gruber CEM, Giombini E, Selleri M, Tausch SH, Andrusch A, Tyshaieva A, Cardeti G, Lorenzetti R, De

- Marco L, Carletti F, Nitsche A, Capobianchi MR, Ippolito G, Autorino GL, Castilletti C. Whole Genome Characterization of Orthopoxvirus (OPV) Abatino, a Zoonotic Virus Representing a Putative Novel Clade of Old World Orthopoxviruses. *Viruses*. 10(10), 2018.
26. Minosse C, Selleri M, Giombini E, Bartolini B, Capobianchi MR, Cerilli S, Loiacono L, Taibi C, D'Offizi G, McPhee F, Garbuglia A. Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents. *Infect Drug Resist*. 11:2117-2127, 2018.
  27. Vairo F, Mammone A, Lanini S, Nicastrì E, Castilletti C, Carletti F, Puro V, Di Lallo D, Panella V, Varrenti D, Scaramozzino P, Di Caro A, Scognamiglio P, Capobianchi MR, Ippolito G; Chikungunya Lazio Outbreak Group. Local transmission of chikungunya in Rome and the Lazio region, Italy. *PLoS One*. 13:e0208896, 2018.
  28. Colavita F, Vita S, Lalle E, Carletti F, Bordi L, Vincenti D, Pozzetto I, Aiuti M, Vairo F, Capobianchi MR, Lichtner M, Castilletti C. Overproduction of IL-6 and Type-I IFN in a Lethal Case of Chikungunya Virus Infection in an Elderly Man During the 2017 Italian Outbreak. *Open Forum Infect Dis*. 5:ofy276, 2018.
  29. Guzzetta G, Minosse C, Pisapia R, Giombini E, Mammone A, Vairo F, Garbuglia AR, Scognamiglio P, Capobianchi MR, Merler S, Ippolito G, Lanini S. Household transmission and disease transmissibility of a large HAV outbreak in Lazio, Italy, 2016-2017. *Epidemics*. 2019 Dec;29:100351.
  30. Puzelli S, Di Martino A, Facchini M, Fabiani C, Calzoletti L, Di Mario G, Palmieri A, Affanni P, Camilloni B, Chironna M, D'Agaro P, Giannecchini S, Pariani E, Serra C, Rizzo C, Bella A, Donatelli I, Castrucci MR; Italian Influenza Laboratory Network. Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004-2017. *BMC Infect Dis*. 2019 Nov 21;19(1):990.
  31. Taramasso L, Lorenzini P, Di Biagio A, Lichtner M, Marchetti G, Rossotti R, Lapadula G, Cozzi-Lepri A, Vichi F, Antinori A, Bonora S, d'Arminio Monforte A; ICONA Foundation Study Group. Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. *J Antimicrob Chemother*. 2019 Nov 1;74(11):3295-3304.
  32. Grebe E, Facente SN, Bingham J, Pilcher CD, Powrie A, Gerber J, Priede G, Chibawara T, Busch MP, Murphy G, Kassanjee R, Welte A; Consortium for the Evaluation and Performance of HIV Incidence Assays (CEPHIA). Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool. *BMC Infect Dis*. 2019 Oct 26;19(1):894.
  33. Gruber CEM, Bartolini B, Castilletti C, Mirazimi A, Hewson R, Christova I, Avšič T, Grunow R, Papa A, Sánchez-Seco MP, Kopmans M, Ippolito G, Capobianchi MR, Reusken CBEM, Di Caro A. Geographical Variability Affects CCHFV Detection by RT-PCR: A Tool for In-Silico Evaluation of Molecular Assays. *Viruses*. 2019 Oct 16;11(10). pii: E953.
  34. Shanyinde M, Girardi E, Puoti M, De Luca A, Sighinolfi L, Caterina UF, Caramello P, Lampe FC, D'Arminio Monforte A, Cozzi-Lepri A; ICONA Foundation Study Group. Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? *BMC Public Health*. 2019 Oct 15;19(1):1291.
  35. Bordoni V, Lalle E, Colavita F, Baiocchi A, Nardacci R, Falasca L, Carletti F, Cimini E, Bordi L, Kobinger G, D'Ambrosio V, Natale F, Giancotti A, Manganaro L, Del Nonno F, Zumla A, Liuzzi G, Ippolito G, Capobianchi MR, Agrati C, Castilletti C. Rescue of Replication-Competent ZIKV Hidden in Placenta-Derived Mesenchymal Cells Long After the Resolution of the Infection. *Open Forum Infect Dis*. 2019 Oct 9;6(10):ofz342.
  36. Sidoti F, Piralla A, Costa C, Scarasciulli ML, Calvario A, Conaldi PG, Paba P, Perno CF, Gaeta A, Antonelli G, Sodano G, Santangelo R, Sanguinetti M, Vatteroni ML, Barzon L, Palù G, Abbate I, Capobianchi MR, Piccirilli G, Lazzarotto T, Baldanti F, Cavallo R. Collaborative national multicenter for the identification of conversion factors from copies/mL to international units/mL for the normalization of HCMV DNA load. *Diagn Microbiol Infect Dis*. 2019 Oct;95(2):152-158.
  37. Enan KA, Minosse C, El Hussein ARM, Selleri M, Giombini E, Capobianchi MR, Elkhidir IM, Mustafa MO, Khair OM, Hassan DA, Garbuglia AR. Analysis of hepatitis B virus-mixed genotype infection by ultra deep pyrosequencing in Sudanese patients, 2015-2016. *Infection*. 2019 Oct;47(5):793-803.
  38. Cimini E, Sacchi A, De Minicis S, Bordoni V, Casetti R, Grassi G, Colavita F, Castilletti C, Capobianchi MR, Ippolito G, Desimio MG, Doria M, Agrati C. Vδ2 T-Cells Kill ZIKV-Infected Cells by NKG2D-Mediated Cytotoxicity. *Microorganisms*. 2019 Sep 12;7(9). pii: E350.
  39. Gianotti N, Lorenzini P, Cozzi-Lepri A, De Luca A, Madeddu G, Sighinolfi L, Pinnetti C, Santoro C, Meraviglia P, Mussini C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm<sup>3</sup> and HIV-RNA >5 log<sub>10</sub> copies/mL. *J Antimicrob Chemother*. 2019 Sep 1;74(9):2732-2741.
  40. Lalle E, Biava M, Nicastrì E, Colavita F, Di Caro A, Vairo F, Lanini S, Castilletti C, Langer M, Zumla A, Kobinger G, Capobianchi MR, Ippolito G. Pulmonary Involvement during the Ebola Virus Disease. *Viruses*. 2019 Aug 24;11(9). pii: E780.
  41. Lanini S, Bartolini B, Taibi C, Agresta A, Garbuglia AR, Montaldo C, Pisapia R, D'Offizi G, Scognamiglio P, Capobianchi MR, Zumla A, Ippolito G. Early improvement of glycaemic control after virus clearance in patients with chronic hepatitis C and severe liver fibrosis: a cohort study. *New Microbiol*. 2019 Jul;42(3):139-

144. Epub 2019 Jul 15.
42. Colavita F, Biava M, Castilletti C, Lanini S, Miccio R, Portella G, Vairo F, Ippolito G, Capobianchi MR, Di Caro A, Lalle E. Inflammatory and Humoral Immune Response during Ebola Virus Infection in Survivor and Fatal Cases Occurred in Sierra Leone during the 2014-2016 Outbreak in West Africa. *Viruses*. 2019 Apr 23;11(4). pii: E373.
  43. Lapa D, Garbuglia AR, Capobianchi MR, Del Porto P. Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay? *Cells*. 2019 Apr 3;8(4). pii: E305.
  44. Sias C, Salichos L, Lapa D, Del Nonno F, Baiocchini A, Capobianchi MR, Garbuglia AR. Alpha, Beta, gamma human PapillomaViruses (HPV) detection with a different sets of primers in oropharyngeal swabs, anal and cervical samples. *Virol J*. 2019 Mar 4;16(1):27.
  45. Matusali G, Colavita F, Bordi L, Lalle E, Ippolito G, Capobianchi MR, Castilletti C. Tropism of the Chikungunya Virus. *Viruses*. 2019 Feb 20;11(2). pii: E175.
  46. Lapa D, Agrati C, Scognamiglio P, Cimini E, Capobianchi MR, Garbuglia AR. GB virus type C cross-reactivity in clinical samples with a low hepatitis C virus antibody positive response. *APMIS*. 2019 Feb;127(2):109-111.
  47. d'Arminio Monforte A, Diaz-Cuervo H, De Luca A, Maggiolo F, Cingolani A, Bonora S, Castagna A, Girardi E, Antinori A, Lo Caputo S, Guaraldi G, Cozzi-Lepri A; ICONA Foundation Study Group. Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. *HIV Med*. 2019 Feb;20(2):99-109.
  48. Lapa D, Beltrame A, Arzese A, Carletti F, Di Caro A, Ippolito G, Capobianchi MR, Castilletti C. Orthopoxvirus Seroprevalence in Cats and Veterinary Personnel in North-Eastern Italy in 2011. *Viruses*. 2019 Jan 25;11(2). pii: E101.
  49. Marrone G, Biolato M, Mercurio G, Capobianchi MR, Garbuglia AR, Liguori A, Vassallo G, Gasbarrini A, Miele L, Grieco A. Acute HEV hepatitis: clinical and laboratory diagnosis. *Eur Rev Med Pharmacol Sci*. 2019 Jan;23(2):764-770.
  50. Bartolini B, Gruber CE, Koopmans M, Avšič T, Bino S, Christova I, Grunow R, Hewson R, Korukluoglu G, Lemos CM, Mirazimi A, Papa A, Sanchez-Seco MP, Sauer AV, Zeller H, Nisii C, Capobianchi MR, Ippolito G, Reusken CB, Di Caro A. Laboratory management of Crimean-Congo haemorrhagic fever virus infections: perspectives from two European networks. *Euro Surveill*. 2019 Jan;24(5).
  51. Carletti F, Colavita F, Rovida F, Percivalle E, Baldanti F, Ricci I, De Liberato C, Rosone F, Messina F, Lalle E, Bordi L, Vairo F, Capobianchi MR, Ippolito G, Cappiello G, Spanò A, Meschi S, Castilletti C. Expanding Usutu virus circulation in Italy: detection in the Lazio region, central Italy, 2017 to 2018. *Euro Surveill*. 2019 Jan;24(3).
  52. Mondì A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort. *J Int AIDS Soc*. 2019 Jan;22(1):e25227.
  53. Knoester M, Helfferich J, Poelman R, Van Leer-Buter C, Brouwer OF, Niesters HGM; 2016 EV-D68 AFM Working Group. Twenty-nine Cases of Enterovirus-D68-associated Acute Flaccid Myelitis in Europe 2016: A Case Series and Epidemiologic Overview. *Pediatr Infect Dis J*. 2019 Jan;38(1):16-21.

I hereby authorize the use of my personal data in accordance to the GDPR 679/16

Rome, December 16, 2019

A handwritten signature in blue ink, appearing to read "Maurizio Capobianchi".